RecruitingSARS-CoV-2
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
Eligible age
0.5–11 yrs
Accepts
All genders
Locations
9 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to \<12 years to determine the optimal dose level per age group.
Sponsor: ModernaTX, Inc.
Where it's recruiting
California
Ontario
Florida
Miami · Miami Lakes · Tamarac
Illinois
Chicago
Michigan
Southfield
Ohio
South Euclid
Texas
Beaumont · Brownsville
Utah
South Ogden
Virginia
Richmond
Washington
Seattle
Source: ClinicalTrials.gov · NCT07808697 · last updated 2026-11-09